{"success":true,"data":{"pressRelease":{"id":"141884","rtpr_id":"nPn8p3JZBa-20260911","ticker":"BHVN","exchange":"NYSE","all_tickers":["BHVN"],"title":"Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)","author":"PR Newswire","published_at":"2026-09-11T22:28:00.029Z","article_body":"Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)\nPR Newswire\n\nNEW YORK, Sept. 11, 2026\n\nBiohaven shares gave up nearly 15% in a single session on September 10, 2026\nfollowing the FDA's partial clinical hold on new-patient enrollment in the\nBHV-7000/opakalim epilepsy trials\n\nNEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped\n$2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that\nthe FDA placed a partial clinical hold on new-patient enrollment in the\nCompany's BHV-7000/opakalim epilepsy trials. Shareholders who lost money on\nBHVN are encouraged to submit their losses for review now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=328353351&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=submit+their+losses+for+review+now)\n, or contact Joseph E. Levi, Esq. by telephone at (888) SueWallSt.\n\nIn BHVN's release disclosing the partial hold, the Company indicated that \"an\nupdate was provided to global regulatory authorities\" regarding ongoing\nnonclinical studies and rodent testing. The FDA reportedly \"determined that\nthere was insufficient information related to a specific metabolite to assess\nrisks.\" As a result of the partial hold, new patient enrollment has been\npaused, but dosing will continue across patients \"already randomized across\nthe BHV-7000 program.\"\n\nPreviously, on August 10, 2026, Biohaven's provided business update\nhighlighted the drug \"continued to demonstrate a favorable safety profile\" in\nits proof of concept study. On August 26, 2026, the Company announced a global\nlicensing agreement with SK Biopharmaceuticals covering opakalim valued at up\nto approximately $795 million. Fifteen days later, the FDA hold was disclosed.\n\nInvestors who purchased Biohaven shares and suffered losses can have their\nBHVN losses evaluated at no cost\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=1285845019&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=have+their+BHVN+losses+evaluated+at+no+cost)\n or reach Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the BHVN Investigation\n\nQ: How much did BHVN stock drop?A: Shares fell approximately 14.73% on\nSeptember 10, 2026 after the Company disclosed that the FDA had placed a\npartial clinical hold on new-patient enrollment in its BHV-7000/opakalim\nepilepsy trials. Investors who purchased shares and suffered losses may be\neligible to seek recovery.\n\nQ: Who is eligible to participate in the BHVN investigation?A: Investors who\npurchased BHVN stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: Who is conducting the BHVN investigation?A: Levi & Korsinsky, LLP is\ninvestigating potential securities claims on behalf of investors who purchased\nBHVN securities. The firm is nationally recognized, ranked in the ISS Top 50\nfor seven consecutive years, and has recovered hundreds of millions of dollars\nfor aggrieved investors.\n\nQ: What do BHVN investors need to do right now?A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=3605571169&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate?A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my BHVN shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought BHVN and sold at a loss may still participate in\nthe investigation.\n\nQ: What does it cost me to participate?A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States?A: U.S. securities investigations\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html\n(https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2944039\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn8p3JZBa-20260911","title":"Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)","author":"PR Newswire","ticker":"BHVN","created":"2026-09-11T22:28:00.029Z","tickers":["BHVN"],"exchange":"NYSE","article_body":"Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)\nPR Newswire\n\nNEW YORK, Sept. 11, 2026\n\nBiohaven shares gave up nearly 15% in a single session on September 10, 2026\nfollowing the FDA's partial clinical hold on new-patient enrollment in the\nBHV-7000/opakalim epilepsy trials\n\nNEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped\n$2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that\nthe FDA placed a partial clinical hold on new-patient enrollment in the\nCompany's BHV-7000/opakalim epilepsy trials. Shareholders who lost money on\nBHVN are encouraged to submit their losses for review now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=328353351&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=submit+their+losses+for+review+now)\n, or contact Joseph E. Levi, Esq. by telephone at (888) SueWallSt.\n\nIn BHVN's release disclosing the partial hold, the Company indicated that \"an\nupdate was provided to global regulatory authorities\" regarding ongoing\nnonclinical studies and rodent testing. The FDA reportedly \"determined that\nthere was insufficient information related to a specific metabolite to assess\nrisks.\" As a result of the partial hold, new patient enrollment has been\npaused, but dosing will continue across patients \"already randomized across\nthe BHV-7000 program.\"\n\nPreviously, on August 10, 2026, Biohaven's provided business update\nhighlighted the drug \"continued to demonstrate a favorable safety profile\" in\nits proof of concept study. On August 26, 2026, the Company announced a global\nlicensing agreement with SK Biopharmaceuticals covering opakalim valued at up\nto approximately $795 million. Fifteen days later, the FDA hold was disclosed.\n\nInvestors who purchased Biohaven shares and suffered losses can have their\nBHVN losses evaluated at no cost\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=1285845019&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=have+their+BHVN+losses+evaluated+at+no+cost)\n or reach Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the BHVN Investigation\n\nQ: How much did BHVN stock drop?A: Shares fell approximately 14.73% on\nSeptember 10, 2026 after the Company disclosed that the FDA had placed a\npartial clinical hold on new-patient enrollment in its BHV-7000/opakalim\nepilepsy trials. Investors who purchased shares and suffered losses may be\neligible to seek recovery.\n\nQ: Who is eligible to participate in the BHVN investigation?A: Investors who\npurchased BHVN stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: Who is conducting the BHVN investigation?A: Levi & Korsinsky, LLP is\ninvestigating potential securities claims on behalf of investors who purchased\nBHVN securities. The firm is nationally recognized, ranked in the ISS Top 50\nfor seven consecutive years, and has recovered hundreds of millions of dollars\nfor aggrieved investors.\n\nQ: What do BHVN investors need to do right now?A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4772553-1&h=3605571169&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fbiohaven-ltd-investigation-bhvn%3Fprid%3D206110%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate?A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my BHVN shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought BHVN and sold at a loss may still participate in\nthe investigation.\n\nQ: What does it cost me to participate?A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States?A: U.S. securities investigations\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html\n(https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2944039\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-11T22:28:00.084601602Z","server_sent_at_ms":1789165680084},"received_at":"2026-09-11T22:28:00.139Z","source_url":"https://www.prnewswire.com/news-releases/biohaven-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-biohaven-bhvn-302876666.html"},"analysis":{"id":"130720","press_release_id":"141884","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["FDA partial clinical hold on new-patient enrollment in BHV-7000/opakalim epilepsy trials","FDA cited insufficient information on a specific metabolite; nonclinical and rodent testing still ongoing","shares fell ~14.73% on the hold disclosure","SK Biopharmaceuticals licensing deal (up to ~$795M) was announced only 15 days before the hold"],"eventType":"legal_litigation","narrative":"SueWallSt.com, a platform powered by plaintiff securities firm Levi & Korsinsky, announced it is investigating potential claims on behalf of Biohaven (BHVN) investors who lost money — no class action has been certified and no lawsuit or settlement is announced.\n\nThe solicitation follows a 14.73% one-day drop ($2.21) on September 10, 2026, after Biohaven disclosed an FDA partial clinical hold pausing new-patient enrollment in the BHV-7000/opakalim epilepsy trials; the FDA cited insufficient information on a specific metabolite, while dosing continues in already-randomized patients.\n\nThe release adds no new issuer disclosure beyond the previously announced hold and the August 26 licensing deal with SK Biopharmaceuticals valued at up to roughly $795 million — treat this as law-firm marketing rather than company news.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation riding the FDA partial-clinical-hold news -- suppress; the underlying FDA hold on BHV-7000/opakalim enrollment is the real catalyst to track."},"keyFigures":{"drugName":"BHV-7000 (opakalim)","customDimensions":{"stock_drop_pct":"14.73%","stock_drop_usd":"$2.21","sk_biopharma_deal_value":"up to approximately $795 million"}},"quotedText":"insufficient information related to a specific metabolite","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP / SueWallSt contact"}],"products":["BHV-7000","opakalim"],"companies":[{"name":"Biohaven Ltd","ticker":"BHVN","relationship":"subject of law-firm investigation"},{"name":"SueWallSt.com","relationship":"plaintiff law-firm platform (release source)"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff securities law firm conducting the investigation"},{"name":"SK Biopharmaceuticals","relationship":"licensing partner (opakalim agreement)"}],"dollarAmounts":[{"amount":"$2.21","context":"share price decline on September 10, 2026 (~14.73%)"},{"amount":"up to approximately $795 million","context":"global licensing agreement with SK Biopharmaceuticals covering opakalim"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued under SueWallSt.com (powered by Levi & Korsinsky LLP) seeking shareholders who lost money on BHVN. No certified class, filed lawsuit, or settlement is announced; the release merely repackages the previously disclosed FDA partial clinical hold."},"tickerRelevance":{"others":[],"primary":"BHVN"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"lawFirm":"Levi & Korsinsky (SueWallSt)","tickerTier":"mid-cap biotech with retail interest","eventGravity":"law-firm-solicitation","classCertified":false,"issuerAuthored":false,"settlementValue":null,"underlyingCatalyst":"FDA partial clinical hold on BHV-7000/opakalim epilepsy trials"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt.com, a platform powered by plaintiff securities firm Levi & Korsinsky, announced it is investigating potential claims on behalf of Biohaven (BHVN) investors who lost money — no class action has been certified and no lawsuit or settlement is announced.\n\nThe solicitation follows a 14.73% one-day drop ($2.21) on September 10, 2026, after Biohaven disclosed an FDA partial clinical hold pausing new-patient enrollment in the BHV-7000/opakalim epilepsy trials; the FDA cited insufficient information on a specific metabolite, while dosing continues in already-randomized patients.\n\nThe release adds no new issuer disclosure beyond the previously announced hold and the August 26 licensing deal with SK Biopharmaceuticals valued at up to roughly $795 million — treat this as law-firm marketing rather than company news.","key_figures":{"drugName":"BHV-7000 (opakalim)","customDimensions":{"stock_drop_pct":"14.73%","stock_drop_usd":"$2.21","sk_biopharma_deal_value":"up to approximately $795 million"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP / SueWallSt contact"}],"products":["BHV-7000","opakalim"],"companies":[{"name":"Biohaven Ltd","ticker":"BHVN","relationship":"subject of law-firm investigation"},{"name":"SueWallSt.com","relationship":"plaintiff law-firm platform (release source)"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff securities law firm conducting the investigation"},{"name":"SK Biopharmaceuticals","relationship":"licensing partner (opakalim agreement)"}],"dollarAmounts":[{"amount":"$2.21","context":"share price decline on September 10, 2026 (~14.73%)"},{"amount":"up to approximately $795 million","context":"global licensing agreement with SK Biopharmaceuticals covering opakalim"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-11T22:28:29.738Z","global_importance":18,"audience_relevance":15,"importance_components":{"lawFirm":"Levi & Korsinsky (SueWallSt)","tickerTier":"mid-cap biotech with retail interest","eventGravity":"law-firm-solicitation","classCertified":false,"issuerAuthored":false,"settlementValue":null,"underlyingCatalyst":"FDA partial clinical hold on BHV-7000/opakalim epilepsy trials"}},"durationMs":29588,"modelName":"glm-5.3-flash"}}